These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 17640598

  • 1. Vascular endothelial growth factor and activin-a serum levels following allogeneic hematopoietic stem cell transplantation.
    Nachbaur D, Schumacher P, Auberger J, Clausen J, Kircher B.
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):942-7. PubMed ID: 17640598
    [Abstract] [Full Text] [Related]

  • 2. Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation.
    Min CK, Kim SY, Lee MJ, Eom KS, Kim YJ, Kim HJ, Lee S, Cho SG, Kim DW, Lee JW, Min WS, Kim CC, Cho CS.
    Bone Marrow Transplant; 2006 Jul; 38(2):149-56. PubMed ID: 16751784
    [Abstract] [Full Text] [Related]

  • 3. Vascular endothelial growth factor gene polymorphisms may predict the risk of acute graft-versus-host disease following allogeneic transplantation: preventive effect of vascular endothelial growth factor gene on acute graft-versus-host disease.
    Kim DH, Lee NY, Lee MH, Sohn SK.
    Biol Blood Marrow Transplant; 2008 Dec; 14(12):1408-16. PubMed ID: 19041064
    [Abstract] [Full Text] [Related]

  • 4. The interleukin-6 and vascular endothelial growth factor in hematopoietic stem cell transplantation.
    Azarpira N, Dehghani M, Darai M.
    Saudi J Kidney Dis Transpl; 2012 May; 23(3):521-5. PubMed ID: 22569438
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Endothelial cell-derived microparticles in allogeneic hematopoietic stem cell recipients.
    Pihusch V, Rank A, Steber R, Pihusch M, Pihusch R, Toth B, Hiller E, Kolb HJ.
    Transplantation; 2006 May 27; 81(10):1405-9. PubMed ID: 16732177
    [Abstract] [Full Text] [Related]

  • 8. Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.
    Fuji S, Kim SW, Fukuda T, Mori S, Yamasaki S, Morita-Hoshi Y, Ohara-Waki F, Heike Y, Tobinai K, Tanosaki R, Takaue Y.
    Biol Blood Marrow Transplant; 2008 May 27; 14(5):510-7. PubMed ID: 18410893
    [Abstract] [Full Text] [Related]

  • 9. Level of vascular endothelial growth factor predicts both relapse and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.
    Moiseev IS, Lapin SV, Surkova EA, Lerner MY, Vavilov VN, Afanasyev BV.
    Biol Blood Marrow Transplant; 2013 Dec 27; 19(12):1677-82. PubMed ID: 24035780
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
    Heinzelmann F, Lang PJ, Ottinger H, Faul C, Bethge W, Handgretinger R, Bamberg M, Belka C.
    Int J Radiat Oncol Biol Phys; 2008 Feb 01; 70(2):523-8. PubMed ID: 17869449
    [Abstract] [Full Text] [Related]

  • 14. Patterns of C-reactive protein release following allogeneic stem cell transplantation are correlated with leukemic relapse.
    Min CK, Kim SY, Eom KS, Kim YJ, Kim HJ, Lee S, Kim DW, Lee JW, Min WS, Kim CC.
    Bone Marrow Transplant; 2006 Mar 01; 37(5):493-8. PubMed ID: 16435015
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J.
    J Clin Oncol; 2008 Feb 01; 26(4):577-84. PubMed ID: 18086801
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.